SUPPLEMENTARY TABLE. Measles Surveillance indicators and targets, by country, area or epidemiologic block* — World Health Organization Western Pacific Region, 2013 and 2017 [table for Progress Toward Measles Elimination — Western Pacific Region, 2013–2017]
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

SUPPLEMENTARY TABLE. Measles Surveillance indicators and targets, by country, area or epidemiologic block* — World Health Organization Western Pacific Region, 2013 and 2017 [table for Progress Toward Measles Elimination — Western Pacific Region, 2013–2017]

Filetype[PDF-70.06 KB]


English
Details Supporting Files You May Also Like

Details:

  • Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.)Immunization Services Division.
  • Description:
    Background: Approaches to controlling emerging antibiotic resistance in health care settings have evolved over time. When resistance to broad-spectrum antimicrobials mediated by extended-spectrum β-lactamases (ESBLs) arose in the 1980s, targeted interventions to slow spread were not widely promoted. However, when Enterobacteriaceae with carbapenemases that confer resistance to carbapenem antibiotics emerged, directed control efforts were recommended. These distinct approaches could have resulted in differences in spread of these two pathogens. CDC evaluated these possible changes along with initial findings of an enhanced antibiotic resistance detection and control strategy that builds on interventions developed to control carbapenem resistance.

    Methods: Infection data from the National Healthcare Safety Network from 2006–2015 were analyzed to calculate changes in the annual proportion of selected pathogens that were nonsusceptible to extended-spectrum cephalosporins (ESBL phenotype) or resistant to carbapenems (carbapenem-resistant Enterobacteriaceae [CRE]). Testing results for CRE and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are also reported.

    Results: The percentage of ESBL phenotype Enterobacteriaceae decreased by 2% per year (risk ratio [RR] = 0.98, p<0.001); by comparison, the CRE percentage decreased by 15% per year (RR = 0.85, p<0.01). From January to September 2017, carbapenemase tTesting was performed for 4,442 CRE and 1,334 CRPA isolates; 32% and 1.9%, respectively, were carbapenemase producers. In response, 1,489 screening tests were performed to identify asymptomatic carriers; 171 (11%) were positive.

    Conclusions: The proportion of Enterobacteriaceae infections that were CRE remained lower and decreased more over time than the proportion that were ESBL phenotype. This difference might be explained by the more directed control efforts implemented to slow Transmission of CRE than those applied for ESBL-producing strains. Increased detection and aggressive early response to emerging antibiotic resistance threats have the potential to slow further spread.

    Suggested citation for this article: Woodworth KR, Walters MS, Weiner LM, et al. Vital Signs: Containment of Novel Multidrug-Resistant Organisms and Resistance Mechanisms — United States, 2006–2017. MMWR Morb Mortal Wkly Rep. ePub: 3 April 2018. DOI: http://dx.doi.org/10.15585/mmwr.mm6713e1.

  • Subjects:
  • Series:
    MMWR. Morbidity and Mortality Weekly Report ; v. 67, no. 17
  • Document Type:
    Journal Article
  • Genre:
    Tables
  • Place as Subject:
    United States
  • Pages in Document:
    1 table
  • Volume:
    67
  • Issue:
    17
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

You May Also Like

Checkout today's featured content at stacks.cdc.gov